Stock Reaction
Radiopharm Theranostics Ltd ADR (NASDAQ:RADX) experienced a 21% decline in its share price on Friday following the announcement of a dilutive capital raise of up to US$13 million through simultaneous offerings in the United States and Australia.
Offering Structure
The company entered into a Securities Purchase Agreement with accredited U.S. institutional investors to issue 1,281,646 American Depositary Shares (ADS) at a price of US$3.16 per ADS in a registered direct offering. Each ADS represents 300 ordinary shares, and the transaction is expected to generate approximately US$4.1 million in gross proceeds before deduction of fees and expenses.
In a concurrent private placement under the same agreement, Radiopharm will issue unregistered warrants that give the holder the right to purchase up to 1,281,646 ADS. The warrants carry an exercise price of US$3.79 per ADS, will expire on 31 July 2029, and become exercisable only after shareholder approval of the issuance of the ordinary shares underlying the ADSs upon exercise.
Timeline and Advisors
The combined offering is slated to close on or about 28 July 2026, subject to customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive U.S. placement agent for the transaction.
Company Overview
Radiopharm Theranostics Ltd is a clinical‑stage biopharmaceutical company focused on developing oncology radiopharmaceuticals for high‑unmet‑need cancer indications. Its pipeline comprises platform technologies based on peptides, small molecules and monoclonal antibodies, with a clinical program that includes one Phase 2 trial and five Phase 1 trials targeting solid tumours such as lung, breast and brain metastases. The company is listed on both the Australian Securities Exchange (ASX:RAD) and the Nasdaq.